Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
The Zacks Analyst Blog JPMorgan, Johnson & Johnson, Applied Materials and Value Line
06:26am, Thursday, 12'th Mar 2026
JPMorgan, Johnson & Johnson and Applied Materials stand out in new research reports, highlighting strong business momentum despite industry and macro headwinds.
Capital International Inc. CA Takes Position in Johnson & Johnson $JNJ
05:10am, Thursday, 12'th Mar 2026
Capital International Inc. CA bought a new position in shares of Johnson and Johnson (NYSE: JNJ) in the undefined quarter, according to the company in its most recent filing with the Securities and Ex
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
01:21pm, Wednesday, 11'th Mar 2026
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity
09:36am, Wednesday, 11'th Mar 2026
Our position in American pharmaceutical company, Eli Lilly & Company (1.8%), was a top contributor to relative returns during the fourth quarter. Our position in global semiconductor company, Advanced
What Happens to Dividend Income When the Next Recession Hits
08:55am, Wednesday, 11'th Mar 2026
Recession fears have a way of making income investors second-guess everything, and if dividends are paid out of cash flow, and cash flow shrinks during economic downturns, it only seems logical that d
Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats
08:10am, Wednesday, 11'th Mar 2026
The stock market could face serious trouble in 2026 as extreme valuations collide with geopolitical tensions, AI investment skepticism, and policy headwinds.
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:10pm, Tuesday, 10'th Mar 2026
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
12:35pm, Tuesday, 10'th Mar 2026
J&J gains EU approval to expand Akeega use to treat patients with BRCA-mutated metastatic hormone-sensitive prostate cancer.
Clarkston Capital Partners LLC Increases Stake in Johnson & Johnson $JNJ
05:54am, Monday, 09'th Mar 2026
Clarkston Capital Partners LLC lifted its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.3% during the undefined quarter, according to the company in its most recent filing with the SEC. T
2,641 Shares in Johnson & Johnson $JNJ Acquired by DLD Asset Management LP
05:08am, Monday, 09'th Mar 2026
DLD Asset Management LP purchased a new stake in shares of Johnson and Johnson (NYSE: JNJ) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm purch
Bell Asset Management Ltd Trims Holdings in Johnson & Johnson $JNJ
03:36am, Monday, 09'th Mar 2026
Bell Asset Management Ltd lowered its stake in shares of Johnson and Johnson (NYSE: JNJ) by 37.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 15,001 shar
2 No-Brainer Dividend Stocks to Buy in 2026
12:27pm, Sunday, 08'th Mar 2026
Johnson & Johnson owes its impressive dividend streak largely to its strong, innovative business. Zoetis should overcome the headwinds it faced last year and profit from a key long-term tailwind.
These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders
12:06pm, Sunday, 08'th Mar 2026
Dividend stocks have more than doubled the average annual return of non-payers, when looking back more than half a century. Wall Street's premier nominal-dollar dividend payers are brand-name business
First Trust Advisors LP Raises Holdings in Johnson & Johnson $JNJ
05:28am, Saturday, 07'th Mar 2026
First Trust Advisors LP lifted its holdings in Johnson and Johnson (NYSE: JNJ) by 7.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
FDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results
08:53am, Friday, 06'th Mar 2026
FDA approves Johnson and Johnson's Tecvayli with Darzalex Faspro for multiple myeloma after strong Phase 3 survival results.
